Total treatments with biologics, n (percentage) by diagnosis | |||||||
---|---|---|---|---|---|---|---|
n (percentage) by diagnosis in BIOBADASER | Age* | n (percentage), women | Disease duration* | Infliximab | Etanercept | Adalimumab | |
Rheumatoid arthritis | 4,006 (68.5) | 54 ± 13 | 3,166 (79.0) | 10 ± 7 | 2,789 (60.6) | 1,170 (25.4) | 577 (12.5) |
All spondylarthritis | 1,524 (26.0) | 45 ± 12† | 537 (35.2)† | 10 ± 8 | 1,180 (70.7) | 472 (28.3) | 15 (0.9)† |
Ankylosing spondylitis | 657 (11.2) | 45 ± 12 | 152 (23.1) | 12 ± 8 | 570 (80.5) | 136 (19.2) | 2 (0.3) |
Psoriatic arthritis | 570 (9.7) | 47 ± 12 | 270 (47.4) | 9 ± 7 | 347 (54.5) | 281 (44.1) | 9 (1.4) |
Undifferentiated spondylarthritis | 187 (3.2) | 43 ± 12 | 70 (37.4) | 8 ± 7 | 162 (79.0) | 41 (20.0) | 2 (1.0) |
Crohn's disease arthritis | 68 (1.2) | 38 ± 13 | 32 (47.1) | 7 ± 8 | 68 (94.4) | 2 (2.8) | 1 (1.4) |
Juvenile spondylarthritis | 19 (0.3) | 30 ± 12 | 7 (36.8) | 17 ± 14 | 17 (89.5) | 2 (10.5) | - |
Reactive arthritis | 12 (0.2) | 49 ± 9 | 2 (16.7) | 8 ± 7 | 10 (83.3) | 2 (16.7) | - |
Chronic seronegative oligoarthritis | 11 (0.2) | 35 ± 9 | 4 (36.4) | 4 ± 3 | 6 (40.0) | 8 (53.3) | 1 (6.7) |